Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

CCL-21

  • Sherven Sharma
  • Maie St. John
  • Jay M. Lee
  • Steven Dubinett
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101560

Synonyms

Historical Background

Chemokines, a group of homologous yet functionally divergent proteins, mediate leukocyte migration and activation, regulate angiogenesis, and impact immune homeostasis and secondary lymphoid organ architecture. Chemokines are classified into four groups (designated CC, CXC, C, and CXXXC), depending on the spacing or presence of four conserved cysteine residues near their amino-terminus. In the CC subgroup, the first two cysteine residues are adjacent, whereas in the CXC subgroup the first 2 cysteine residues are separated by a nonconserved amino acid residue...
This is a preview of subscription content, log in to check access.

References

  1. Ali OA, Huebsch N, Cao L, Dranoff G, Mooney DJ. Infection-mimicking materials to program dendritic cells in situ. Nat Mater. 2009;8:151–8.  https://doi.org/10.1038/nmat2357.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Ashour AE, Lin X, Wang X, Turnquist HR, Burns NM, Tuli A, et al. CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors. Cancer Biol Ther. 2007;6:1206–10. Epub 2007 May 7PubMedCrossRefGoogle Scholar
  3. Baratelli F, Takedatsu H, Hazra S, Peebles K, Luo J, Kurimoto PS, et al. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in Non- Small Cell Lung Cancer. J Transl Med. 2008;6:38.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.  https://doi.org/10.1056/NEJMoa1200694.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348:803–8.  https://doi.org/10.1126/science.aaa3828.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Coppola D, Mule JJ. Ectopic lymph nodes within human solid tumors. J Clin Oncol. 2008;26:4369–70.PubMedCrossRefGoogle Scholar
  7. Correale P, Rotundo MS, Botta C, Del Vecchio MT, Ginanneschi C, Licchetta A, et al. Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. Clin Cancer Res. 2012;18:850–7.  https://doi.org/10.1158/1078-0432.ccr-10-3186.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Cyster J. Chemokines and cell migration in secondary lymphoid organs. Science. 1999;286:2098–102.PubMedCrossRefGoogle Scholar
  9. Delamarre L, Mellman I, Yadav M. Cancer immunotherapy. Neo approaches to cancer vaccines. Science. 2015;348:760–1.  https://doi.org/10.1126/science.aab3465.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26:4410–7.PubMedCrossRefGoogle Scholar
  11. Flanagan K, Moroziewicz D, Kwak H, Horig H, Kaufman HL. The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. Cell Immunol. 2004;231:75–84. Epub 2005 Jan 21PubMedCrossRefGoogle Scholar
  12. Friedman RS, Jacobelli J, Krummel MF. Surface-bound chemokines capture and prime T cells for synapse formation. Nat Immunol. 2006;7:1101–8. Epub 2006 Sep 10PubMedCrossRefGoogle Scholar
  13. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–28.  https://doi.org/10.1056/NEJMoa1501824.CrossRefGoogle Scholar
  14. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;  https://doi.org/10.1200/jco.2014.58.3708.CrossRefGoogle Scholar
  15. Gollmer K, Asperti-Boursin F, Tanaka Y, Okkenhaug K, Vanhaesebroeck B, Peterson JR, et al. CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway. Blood. 2009;114:580–8. Epub 2009 May 18PubMedPubMedCentralCrossRefGoogle Scholar
  16. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–7.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Hu D, Lau OD, Wang L, Wang G, Schaue D, Zhu L, et al. A novel modular polymer platform for the treatment of head and neck squamous cell carcinoma in an animal model. Arch Otolaryngol. 2012;138:412–7.  https://doi.org/10.1001/archoto.2012.20.CrossRefGoogle Scholar
  18. Huebsch N, Mooney DJ. Inspiration and application in the evolution of biomaterials. Nature. 2009;462:426–32.  https://doi.org/10.1038/nature08601.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Kar UK, Srivastava MK, Andersson A, Baratelli F, Huang M, Kickhoefer VA, et al. Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS One. 2011;6:e18758.  https://doi.org/10.1371/journal.pone.0018758.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Kirk C, Hartigan-O'Connor D, Mule J. The Dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res. 2001a;61:8794–802.PubMedPubMedCentralGoogle Scholar
  21. Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, Chamberlain JS, Giedlin M, Aukerman L, et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res. 2001b;61:2062–70.PubMedPubMedCentralGoogle Scholar
  22. Lapteva N, Aldrich M, Rollins L, Ren W, Goltsova T, Chen SY, et al. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther. 2009;17:1626–36. Epub 2009 Jun 16PubMedPubMedCentralCrossRefGoogle Scholar
  23. Lee JM, Garon EB, Lee M, Baratelli F, Wang G, Abtin F, et al. PD-L1 expression correlates with immuneresponse in a Phase I trial of CCL21 gene modified dendritic cell therapy in lung cancer. J ImmunoTherapy Cancer. 2014;2(Suppl 3):O20.CrossRefGoogle Scholar
  24. Li WA, Mooney DJ. Materials based tumor immunotherapy vaccines. Curr Opin Immunol. 2013;25:238–45.  https://doi.org/10.1016/j.coi.2012.12.008.CrossRefPubMedPubMedCentralGoogle Scholar
  25. Liang CM, Zhong CP, Sun RX, Liu BB, Huang C, Qin J, et al. Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity. J Virol. 2007;81:9502–11. Epub 2007 Jun 13PubMedPubMedCentralCrossRefGoogle Scholar
  26. Lin Y, Luo J, Zhu WE, Srivastava M, Schaue D, Elashoff DA, et al. A cytokine-delivering polymer is effective in reducing tumor burden in a head and neck squamous cell carcinoma murine model. Otolaryngology. 2014;151:447–53.  https://doi.org/10.1177/0194599814533775.CrossRefGoogle Scholar
  27. Middel P, Brauneck S, Meyer W, Radzun HJ. Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma. BMC Cancer. 2010;10:578.  https://doi.org/10.1186/1471-2407-10-578.CrossRefPubMedPubMedCentralGoogle Scholar
  28. Miller PW, Sharma S, Stolina M, Butterfield LH, Luo J, Lin Y, et al. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther. 2000;11:53–65.PubMedCrossRefGoogle Scholar
  29. Novak L, Igoucheva O, Cho S, Alexeev V. Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Mol Cancer Ther. 2007;6:1755–64.PubMedCrossRefGoogle Scholar
  30. Peske JD, Thompson ED, Gemta L, Baylis RA, Fu YX, Engelhard VH. Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat Commun. 2015;6:7114.  https://doi.org/10.1038/ncomms8114.CrossRefPubMedPubMedCentralGoogle Scholar
  31. Ross DA, Hundal JS, Son YH, Ariyan S, Shin J, Lowlicht R, et al. Microsurgical free flap reconstruction outcomes in head and neck cancer patients after surgical extirpation and intraoperative brachytherapy. Laryngoscope. 2004;114:1170–6.  https://doi.org/10.1097/00005537-200407000-00007.CrossRefPubMedPubMedCentralGoogle Scholar
  32. Salehi-rad R, Walser TC, Yakobian N, Park SJ, Lee M-H, Lee JM, et al. Intratumoral CCL21 and checkpoint blockade cooperatively inhibit NSCLC tumor growth in vivo to a greater extent than either monotherapy alone. Fourth AACR-IASLC International Joint Conference on Lung Cancer Translational Science from the Bench to the Clinic, 4–7 Jan 2016. Hard Rock Hotel, San DiegoGoogle Scholar
  33. Sharma S, Miller P, Stolina M, Zhu L, Huang M, Paul R, et al. Multi-component gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with Interleukin 7/Herpes Simplex Thymidine Kinase-transduced autologous tumor and ex vivo-activated dendritic cells. Gene Ther. 1997;4:1361–70.PubMedCrossRefGoogle Scholar
  34. Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J immuno. 2000;164:4558–63.CrossRefGoogle Scholar
  35. Soria JC, Marabelle A, Brahmer JR, Gettinger S. Immune checkpoint modulation for non-small cell lung cancer. Clin Cancer Res. 2015;21:2256–62.  https://doi.org/10.1158/1078-0432.ccr-14-2959.CrossRefPubMedPubMedCentralGoogle Scholar
  36. Tatsumi T, Huang J, Gooding WE, Gambotto A, Robbins PD, Vujanovic NL, et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res. 2003;63:6378–86.PubMedPubMedCentralGoogle Scholar
  37. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71.PubMedPubMedCentralCrossRefGoogle Scholar
  38. Turnquist HR, Lin X, Ashour AE, Hollingsworth MA, Singh RK, Talmadge JE, et al. CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. Int J Oncol. 2007;30:631–9.PubMedPubMedCentralGoogle Scholar
  39. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Laboratory investigation. J TechMeth Path. 2014;94:107–16.  https://doi.org/10.1038/labinvest.2013.130.CrossRefGoogle Scholar
  40. Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol. 2000;165:1992–2000.PubMedCrossRefGoogle Scholar
  41. Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res. 2004;10:2891–901.PubMedCrossRefGoogle Scholar
  42. Yousefieh N, Hahto SM, Stephens AL, Ciavarra RP. Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Microenviron. 2009;6:6.Google Scholar
  43. Zeid NA, Muller HK. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology. 1993;25:338–43.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Sherven Sharma
    • 1
    • 2
  • Maie St. John
    • 2
  • Jay M. Lee
    • 2
  • Steven Dubinett
    • 1
    • 2
  1. 1.Molecular Medicine Laboratory, VAGLAHSDavid Geffen School of Medicine at UCLA, JCCC Lung Cancer ProgramLos AngelesUSA
  2. 2.David Geffen School of Medicine at UCLAJCCC Head and Neck Cancer ProgramLos AngelesUSA